Anti-Mouse CD3 – Purified in vivo PLATINUM™ Functional Grade

γ/δ TCR-positive T-T hybridoma D1

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

PhenoCycler-Fusion (CODEX)®
IHC (Frozen) The suggested concentration for this 17A2 antibody in IHC staining on frozen tissue is 5.0 - 10 μg per ml. Titration of the reagent is recommended for optimal performance for each application.

Clone 17A2 recognizes an epitope on mouse CD3.

CD3 is expressed on human peripheral blood lymphocytes, splenic lymphocytes, and the majority of T-CLL and T-ALL cells.

CD3ε is a 20kDa subunit of the TCR complex and is a transmembrane T-cell surface glycoprotein that belongs to the Ig superfamily. It is one of five polypeptide chains that form the TCR complex by associating with the CD3δ, γ and ζ chains, in addition to the TCR α/β or γ/δ chains. CD3 is involved in TCR signaling, enumeration of immunocompetent T-lymphocytes in peripheral blood, and signal transduction during antigen recognition.

Peptide antigen/MHC-complex

Antigen recognition, TCR signal transduction, T cell activation

1. Gallimore, A. et al. (2005) J Immunol. 175(11):7098-102. PubMed
2. Mysliwietz, J. et al. (1992) Blood 80: 2661-2667